Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the thirty-one ratings firms that are covering the firm, MarketBeat reports. Three analysts have rated the stock with a sell recommendation, ten have assigned a hold recommendation, seventeen have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $494.04.
A number of research analysts recently commented on VRTX shares. HC Wainwright dropped their price target on Vertex Pharmaceuticals from $600.00 to $535.00 and set a “buy” rating for the company in a research note on Friday, December 20th. Oppenheimer lowered shares of Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Thursday, December 19th. UBS Group boosted their price objective on shares of Vertex Pharmaceuticals from $562.00 to $586.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. Canaccord Genuity Group raised their target price on Vertex Pharmaceuticals from $361.00 to $408.00 and gave the company a “sell” rating in a report on Wednesday, November 6th. Finally, Bank of America lowered their price target on Vertex Pharmaceuticals from $545.00 to $522.00 and set a “buy” rating for the company in a report on Thursday, December 19th.
Get Our Latest Report on Vertex Pharmaceuticals
Hedge Funds Weigh In On Vertex Pharmaceuticals
Vertex Pharmaceuticals Trading Up 0.3 %
Shares of Vertex Pharmaceuticals stock opened at $407.11 on Wednesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.20 and a current ratio of 2.47. The firm has a 50-day moving average of $456.78 and a 200-day moving average of $470.61. Vertex Pharmaceuticals has a 52-week low of $377.85 and a 52-week high of $519.88. The stock has a market cap of $104.84 billion, a PE ratio of -204.58 and a beta of 0.36.
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last announced its earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.61 by $0.77. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The firm had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.69 billion. During the same quarter in the prior year, the business posted $3.67 EPS. The business’s revenue was up 11.6% compared to the same quarter last year. As a group, sell-side analysts forecast that Vertex Pharmaceuticals will post -1.83 EPS for the current year.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
Recommended Stories
- Five stocks we like better than Vertex Pharmaceuticals
- Best Stocks Under $10.00
- Insiders Are Selling, But These 3 Stocks Are Must-Buys
- Roth IRA Calculator: Calculate Your Potential Returns
- Rivian Defies Doubters: Delivery Triumph Fuels Stock Surge
- Health Care Stocks Explained: Why You Might Want to Invest
- Hindenburg Short Report Slams Carvana Over Alleged ‘Grift’
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.